Introduction
Breast cancer is an increasingly common malignancy with few curative options beyond early detection. In particular, estrogen receptor (ER)-negative breast cancers are unresponsive to antiestrogen therapy and generally more aggressive than ER-positive tumors (Rochefort et al., 2003) . Development of novel, more active chemotherapeutic agents or combination therapies will therefore be an important step in the battle against this disease.
Retinoids are derivatives of vitamin A, which have shown antitumor activity in a variety of in vitro and in vivo models (De Luca et al., 1995; Lippman et al., 1995; Lotan, 1996; Miller, 1998) . All-trans-retinoic acid (RA), a natural and hormonally active vitamin A metabolite, is used in clinical treatment of acute promyelocytic leukemia (APL), and synthetic retinoids are currently in clinical trials for the treatment of other malignancies, including breast cancer.
The molecular mechanisms by which retinoids exert their antiproliferative effects are not fully elucidated, but involve binding to the nuclear retinoic acid receptors, RARs and RXRs. These receptors form RAR/RXR heterodimers or RXR homodimers, which function as ligand-induced transcription factors that switch a variety of genes on and off (Evans, 1988; Mangelsdorf et al., 1995) . Growth inhibition of breast carcinoma cells by RA has been shown to be mediated mainly by activation of the RARa isoform (van der Burg et al., 1993; Fitzgerald et al., 1997) , and to involve downregulation of the estrogen receptor (ERa) and ER target genes (Rubin et al., 1994) , as well as degradation of cyclin D1 (Zhu et al., 1997) . We have also recently reported the importance of a decrease in IRS-1 levels and downstream signaling through the PI3-K/AKT pathway following treatment with RA in the ER-positive cell line MCF-7 (del Rincon et al., 2003) .
ER-negative breast cancer cells are generally resistant to retinoids, and this has been linked to downregulation of RARa levels (Sheikh et al., 1993 (Sheikh et al., , 1994 . However, we have previously reported that sensitivity to RA can be restored in the ER-negative MDA-MB-231 cell line by stable reintroduction of ERa (Rosenauer et al., 1998) or ERb (manuscript submitted), without an increase in RARa levels. Thus, the mechanism of RA-resistance in this cell line is not clear. Given the increasing evidence that shows crosstalk between the activity of nuclear receptors and signal transduction pathways, such as the protein kinase C (PKC), the MAPK and the PI3-K/AKT pathways, we investigated whether altered activity of these pathways may play a role.
PKC represents a family of serine/threonine kinases, which control signal transduction pathways involved in regulation of cell growth, survival and differentiation.
The PKC family comprises at least 12 isoforms, the conventional cPKCs (a, bI, bII and g), the novel nPKCs (d, e, Z, m and y) and the atypical aPKCs (l, i and z). Characteristic for all PKC isoforms is their dependence on lipids (phosphatidylserine, PS) for activity. The cPKCs also require diacylglycerol (DAG) and Ca 2 þ for their activation, whereas the nPKCs are Ca 2 þ independent and the aPKCs are independent of both Ca 2 þ and DAG (Mellor and Parker, 1998; Martelli et al., 1999) . Moreover, activation of the PKC proteins is regulated by three distinct phosphorylation events, in the activation domain, at an autophosphorylation site and (except for the aPKCs) at a hydrophobic C-terminal site (Keranen et al., 1995; Parekh et al., 2000) .
There have been several reports of crosstalk, both positive and negative, between retinoids and PKC. Notably, both PKCa and g can phosphorylate RARa on Ser157, in the extended DNA-binding domain, and this reduces its ability to form an active heterodimer with RXR (Delmotte et al., 1999) . However, PKCa can positively regulate RA-signaling and has been demonstrated to be required for growth inhibition by RA in some cells (Cho et al., 1997; Cho and Talmage, 2001 ). PKCa expression is also increased by RA in many RAsensitive cells (Boskovic et al., 2002) , although we have studied several breast cancer cells lines and found no correlation between expression or induction of PKCa and RA-sensitivity (unpublished observation). A positive interaction between RARa and PKCd was also recently reported. The authors showed that RA can activate PKCd in MCF-7 cells and that overexpression of PKCd increases transcriptional activity from an RARE in these cells (Kambhampati et al., 2003) . On the other hand, RA has been reported to act as a specific ligand for PKCa in vitro, competing with the lipid activator PS, thereby acting as an inhibitor of PKC activity (Radominska-Pandya et al., 2000) . Moreover, it has been shown that the pan-PKC inhibitor staurosporine can potentiate induction of differentiation by RA (Yung and Hui, 1995) .
There is also increasing evidence for crosstalk between retinoid signaling and the MAPK pathways (ERK, p38MAPK and JNK). For example, phosphorylation of RXRa by ERK and JNK can inhibit signaling by RA as well as RXR selective retinoids (Solomon et al., 1999; Lee et al., 2000a; MatsushimaNishiwaki et al., 2001; Li et al., 2002) . On the other hand, RA is known to induce the activation of ERK in certain cell types, and this has been shown to be required for some of its actions, including induction of differentiation and growth arrest (Yen et al., 1998; Bost et al., 2002; Miranda et al., 2002) .
We report here that three inhibitors of PKC, the panselective GF109203X (Toullec et al., 1991) and Go6983 (Gschwendt et al., 1996) , and the PKCd selective Rottlerin (Gschwendt et al., 1994) , have the ability to interact with retinoids in retinoid-resistant MDA-MB-231 cells and cause growth inhibition, partially by inducing apoptosis, in an additive or synergistic manner. We further present evidence that this involves a strong and sustained activation of ERK1/2.
Results

GF109203X
and RA interact to inhibit proliferation and induce apoptosis in a synergistic manner MDA-MB-231 cells were treated with RA, GF or RA þ GF at the indicated concentrations for up to 8 days and total cell number was assessed as described in Materials and methods. Neither RA nor GF had a significant growth inhibitory effect as single agents at any time point. However, the combination caused a marked reduction in cell growth that was apparent by day 3. A maximal inhibition of 80% compared to untreated cells was achieved by day 8 (Figure 1 ). Propidium iodide staining and cell cycle analysis was then performed on cells treated for 24, 48 and 72 h. Treatment with RA þ GF for 24 h showed no significant effect, whereas a 48-h treatment led to partial growth arrest in the G1 phase of the cell cycle (6071.5 vs 5571.4% for control-treated cells), accompanied by a decrease in S phase (3271.3 vs 3771.2%, Po0.05). After 72 h, however, a significant increase in cells with sub-G1 DNA content was observed, indicating that the cells were undergoing apoptosis. This was observed for cells treated with GF in combination with 1 mM RA, but was more pronounced for cells treated with GF plus 10 mM RA (Figure 2a ). Of note, RA alone did not induce apoptosis at any concentration used. To confirm that the cells were indeed undergoing apoptosis, several methods were used. Activation of effector caspases by RA þ GF was shown using a caspase-3 activity assay (Figure 2b ), as well as by the detection of cleavage of the caspase-3/-7 substrate PARP (Figure 2c ). Moreover, membrane changes associated with apoptosis were detected by Annexin V staining (Figure 2d ).
To determine if the combination of RA and GF also induced differentiation of the tumor cells, we examined production of lipid droplets by Oil Red O staining (Le et al., 2000; Adan et al., 2003) in cells treated with RA, GF or RA þ GF for up to 5 days. However, no evidence of differentiation was noted (not shown).
Figure 1 GF109203X and RA synergistically inhibit MDA-MB-231 cell proliferation. The cells were treated with 10 mM RA and 1 mM GF109203X and cell number was assessed using SRB staining as described in Materials and methods. Results from a representative experiment is shown as means7s.d. **Indicates a significant difference compared to all treatments RA and GF109203X cause apoptosis in breast cancer cells F Pettersson et al
GF109203X induces apoptosis in combination with synthetic retinoids
To test whether the effect of GF is specific for RA, cells were treated with GF in combination with two synthetic retinoids. The cells were treated with an RAR-selective retinoid, TTNPB (LG100272), and the more RXRselective retinoid, Bexarotene (Targretin, LGD1069), in the absence or presence of GF. Apoptosis was assessed by PI staining after 72 h, and we show that treatment with TTNPB þ GF as well as Bexarotene þ GF leads to induction of apoptosis, whereas the retinoids alone have no effect (Figure 3a) . The level of apoptosis induced was comparable to that induced by RA þ GF, indicating that activation of RAR/RXR heterodimers (by RA and TTNPB) or RXR homodimers (by Bexarotene) may be involved.
GF enhances RAR-mediated transcription
The fact that RAR selective as well as RXR selective retinoids were shown to cause apoptosis only when combined with GF led us to examine whether GF could alter transcriptional activation from transiently expressed retinoid response elements. Indeed, pretreatment with GF was found to significantly enhance activation by RA of the bRARE-tk-CAT reporter , (Figure 3b ). We also assessed transcriptional activation of CRBPII-tk-CAT, containing the RXRE from the CRBPII promoter (Mangelsdorf et al., 1991) , by Bexarotene þ /À GF. In contrast to its positive effect on bRARE-driven transcription, GF did not affect activation of CRBPII-tk-CAT ( Figure 3b ). GF also had no effect on the expression levels of RARa, RARb or RXRa (data not shown).
GF109203X and RA downregulate PKC expression
Since RA as well as GF can regulate PKC expression and activity, we asked whether growth inhibition and apoptosis may be stimulated through cooperative regulation of PKC by these agents. Expression of phosphorylated PKC was assessed by Western blotting using a phospho-specific PKC antibody that detects PKCa, bI, bII, e, Z and d only when phosphorylated at a carboxy-terminal residue homologous to Ser660 of PKCbII. A single band was detected at an apparent molecular weight of 82 kDa, which represents PKCa, the main isoform expressed in MDA-MB-231 (Platet et al., 1998; Gauthier et al., 2003) . Moreover, in cells treated with GF, a decrease in phosphorylated PKC could be seen. RA alone had no significant effect, but the combination of RA þ GF caused a stronger decrease than GF alone ( Figure 4 , panel 1). Expression levels of total PKCa and d were also examined and it was found that both isoforms were downregulated by GF, and RA alone also caused a small decrease in PKCa levels, but had no effect on PKCd. Moreover, we assessed regulation of PKC mRNA levels and found that while PKCa was slightly downregulated by both RA and GF, PKCd was unaffected (data not shown).
GF109203X causes sustained activation of MAPK pathways
We further examined regulation by RA and GF of signal transduction pathways that lie downstream of PKC. By Western analysis using phospho-specific antibodies, which only react with the activated forms of the proteins, we showed that both ERK1/2 and p38 MAPK activity was significantly increased in MDA-MB-231 cells treated with GF or RA þ GF for 72 h ( Figure 5a ). Using a kinase assay, as described in Materials and methods, it was also shown that RA and GF caused a much weaker activation of JNK ( Figure 5b ). Total levels of ERK, p38 and JNK remained unchanged.
To determine at what time the observed changes in MAPK activity occurred, time-course experiments were performed. We found that ERK was already activated after a 3-h treatment with GF or RA þ GF and that this activation remained high throughout the experiment ( Figure 6 , panel 1). In contrast, significant activation of p38 MAPK was observed only after 24 h, and remained high at 48 and 72 h ( Figure 6 , panel 3). Levels of phosphorylated PKC were also examined, and were found to decrease after 48-72 h ( Figure 6 , panel 4).
Inhibition of the MEK/ERK pathway blocks induction of apoptosis
To further investigate the role of MAPK activation in apoptosis induced by RA þ GF, MDA-MB-231 cells were cotreated with RA, GF and selective MAPK inhibitors for up to 72 h. Remarkably, cotreatment with two different MEK inhibitors, PD98059 and U0126, which specifically block downstream activation of ERK1/2, almost completely blocked the induction of apoptosis by RA þ GF. This was shown by PI staining Figure 7b ). Moreover, addition of PD98059 increased the total cell number (live plus dead cells), compared to RA þ GF (Figure 7c ), indicating that the MEK inhibitor did not simply inhibit apoptosis by growth arresting the cells. This was further confirmed by cell cycle analysis, which showed no effect of PD98059 alone on cell cycle distribution (data not shown). Western blot analysis confirmed that PD98059
and U0126 inhibited activation of ERK under the conditions used (Figure 7d ). The cells were also cotreated with RA, GF and the p38-MAPK inhibitor SB203580, but contrary to the effect of the MEK inhibitors, SB203580 did not block induction of apoptosis. A concentration of 1 mM SB203580 had no effect on apoptosis (not shown) and a concentration of 5 mM increased, rather than decreased, the level of apoptosis observed (Figure 7e ). An inhibitor of JNK, SP600125 (5 mM), had no significant effect on induction of apoptosis by RA þ GF (data not shown). In addition, we assessed whether the MEK inhibitors had an effect on levels of phosphorylated PKC, and found that both PD98059 and U0126 rescued the downregulation caused by RA þ GF (Figure 7f ).
Ability of other PKC inhibitors to inhibit cell proliferation and induce apoptosis in combination with RA correlates with ability to activate ERK Having established that GF can interact with RA to induce apoptosis in MDA-MB-231 cells, and that activation of ERK plays an important role, we wished to investigate if this phenomenon is unique to GF or applies to other inhibitors of PKC as well. Three different inhibitors, Go6983 (Go), UCN-01 and Rottlerin were examined for their ability to interact with RA and cause growth inhibition and apoptosis in MDA-MB-231 cells. Go6983 is a broad-range PKC inhibitor that is similar to GF, whereas UCN-01 inhibits mainly classical PKCs (Hofmann, 2001) , and Rottlerin is selective for PKCd (Gschwendt et al., 1994) . The cells were treated for up to 8 days with each of the inhibitors in the absence or presence of RA and cell proliferation and apoptosis were assessed. Like GF, Go had a weak growth inhibitory effect by itself, but strongly suppressed growth and induced apoptosis in combination with RA (Figure 8a ). UCN-01 had more potent growth inhibitory activity as a single agent than GF or Go, but at no concentration tested did UCN-01 act in an additive or synergistic manner with RA to cause growth inhibition or apoptosis (Figure 8b ). Rottlerin was also a fairly potent growth inhibitor and induced some apoptosis by itself. However, the combination of Rottlerin and RA caused a significantly enhanced inhibition of cell growth and a higher level of apoptosis (Figure 8c ).
Whole cell extracts were also prepared and Western analysis was performed to assess activation of ERK1/2 by Go, UCN-01 and Rottlerin. Consistent with the ability to synergize with RA to induce apoptosis, both Go6983 and Rottlerin caused a sustained activation of ERK1/2 that was apparent within 3-6 h, while UCN-01 had no effect on phospho-ERK1/2 levels ( Figure 8d ).
Downregulation of PKCd using siRNA confers partial responsiveness to RA
Since the PKCd selective inhibitor Rottlerin was found to significantly enhance inhibition of cell growth and apoptosis in response to RA, we tested if selective Expression of phosphorylated PKC was assessed by Western blotting using a phospho-specific PKC antibody. Total levels of PKCa and d were detected using isoform-specific antibodies and a b-actin antibody was used to confirm equal loading. Representative blots using whole cell extracts from MDA-MB-231 treated with 10 mM RA and 1 mM GF109203X for 72 h are shown Figure 5 GF109203X induces a sustained activation of MAPK pathways in MDA-MB-231. (a) Active ERK and p38 were detected in whole cell lysates from cells treated as in Figure 4 , by Western blotting using phospho-specific antibodies. Expression of total ERK2 did not change and was used to confirm equal loading. (b) JNK activity was assessed by a kinase assay as described in Materials and methods, using GST c-Jun as the substrate. Expression of total JNK was assessed by Western blotting downregulation of PKCa or d using small interfering RNA (siRNA) could affect sensitivity to RA. It was observed that while downregulation of either PKCa or d was somewhat toxic to the cells, only siRNA targeted to PKCd conferred some responsiveness to RA. As shown in Figure 9 , treatment with RA for 72 h following transfection with PKCd siRNA led to a significant increase in the percentage of apoptotic cells. However, although PKCd expression was almost completely abolished by siRNA, as determined by Western blotting (Figure 9a ), RA þ GF still caused a significantly stronger apoptotic response than RA alone. This indicates that treatment with GF produces an additional effect that also promotes apoptosis. Of note, downregulation of either PKCa or d using siRNA did not alter phospho-ERK1/2 levels (data not shown).
Discussion
Retinoids have antiproliferative activity against breast cancer cells in vitro and in vivo. However, cells that lack expression of ER and cells with low expression of RARa are usually retinoid resistant. Moreover, clinical trials using retinoids in breast cancer patients have so far shown limited activity.
We report here that MDA-MB-231, an ER-negative and retinoid resistant cell line, can be growth inhibited by the combination of retinoids with pharmacological inhibitors of PKC. This potentiation of growth inhibition involves induction of apoptosis, and appears to be partially mediated through enhanced activation of RAR/RXR-mediated transcription. GF109203X was shown to enhance activation by RA of an RAREdriven reporter construct. In contrast, activation of an RXRE by the RXR selective Bexarotene was unaffected by GF, despite the fact that Bexarotene þ GF induced apoptosis to the same extent as RA þ GF. At the concentration used, it is known that Bexarotene also binds and activates RAR/RXR heterodimers, although with lower affinity than for RXR/RXR homodimers (Kizaki et al., 1996) . Thus, the effect we observed may well be mediated via RAR-regulated transcription. In support of this, a ligand with higher selectivity for RXR, LG101305, failed to induce apoptosis when combined with GF (data not shown). However, effects that are independent of RAR-mediated transcription may also be involved, especially in cells treated with higher retinoid concentrations. Such effects have been reported to be responsible for the induction of apoptosis by synthetic retinoids such as Fenretinide (4-HPR) (Kitareewan et al., 1999; Wu et al., 2001 ) and CD437 (Sun et al., 1999b; Zhao et al., 2001) , as well as by RA (Pepper et al., 2002) . These include formation of DNA adducts, activation of stress kinase pathways, induction of reactive oxygen species and direct effects on mitochondria (Delia et al., 1995; Marchetti et al., 1999; Rigobello et al., 1999; Sun et al., 1999a; Hail et al., 2001; Ortiz et al., 2001; Zhao et al., 2001; Appierto et al., 2004) .
We demonstrated that several PKC inhibitors could interact with retinoids to induce apoptosis in ## Indicates a significant difference between RA þ GF and RA þ GF þ PD (Po0.01)
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MDA-MB-231. There is some contradictory information in the literature concerning expression of the different PKC isoforms in MDA-MB-231. While some authors see no expression of PKCa (Cho et al., 1997) , most reports show that PKCa is the main isoform expressed in these cells (Platet et al., 1998; Gauthier et al., 2003) . In agreement with these reports, our MDA-MB-231 express high levels of PKCa, as well as lower levels of PKCd. We showed that GF109203X decreases the total levels of both PKCa and d, and that RA further potentiates this decrease (Figure 4 ). Treatments (48-72 h) also cause a significant decrease in levels of phospho-PKC (Figures 4 and 6 ). While induction of both PKCa and d expression and activity by RA has been shown in other cell lines, including RA-sensitive breast cancer cells (Cho et al., 1997; Cho and Talmage, 2001; Kambhampati et al., 2003) , we observed a small decrease in PKCa and no effect on PKCd after treatment with RA alone.
Inhibitors of PKC have previously been shown to sensitize cells to apoptosis induced by different cytotoxic drugs (Shao et al., 1997; Huigsloot et al., 2003) and many PKC inhibitors that are currently under development for use in cancer treatment are themselves potent inducers of apoptosis (Shao et al., 1997; Gschwend et al., 2000; Tenzer et al., 2001) . GF is not a strong inducer of apoptosis, but has been shown to potentiate the cytotoxic effects of tumor necrosis factor (TNF) (Basu et al., 2001) and Heregulin (Le et al., 2001) in breast cancer cells, as well as anti-CD95-induced apoptosis in Jurkat T cells (Drew et al., 1998) . In the case of TNF, enhancement of apoptosis by GF occurred in several cell lines, including MDA-MB-231, and was linked to cleavage of PKCd and e (Basu et al., 2001) . Conversely, potentiation of Heregulin-induced apoptosis in the SKBr3 cell line was proposed to be associated with impairment of PKCa activity (Le et al., 2001) . In agreement with this latter report, we observed decreased Three of the PKC inhibitors used in this study, GF, Go and UCN-01, are broad-range inhibitors that affect most PKC isoforms. However, there are some differences between these inhibitors, both structural and functional. UCN-01 is more selective for the cPKCs (a, b, g) than GF and Go (Hofmann, 2001) , and also inhibits cyclin-dependent kinases, PDK-1 and CHK-1 (Kawakami et al., 1996; Busby et al., 2000; Graves et al., 2000; Sato et al., 2002; Sausville, 2003) . In fact, inhibition of cyclin-dependent kinases may explain why UCN-01 was found to have a strong antiproliferative effect in MDA-MB-231 cells, but did not induce apoptosis (see Figure 8b) .
Under our experimental conditions, GF, Go and UCN-01 all decreased the level of phosphorylated PKCa, the main isoform expressed in MDA-MB-231, but only GF and Go caused growth inhibition and apoptosis in combination with RA. Thus, it is clear that decreasing PKCa alone is not sufficient to promote retinoid-induced apoptosis. We went on to test if the PKCd selective inhibitor Rottlerin could interact with RA to induce growth inhibition and apoptosis. We found that it did, which may indicate a role for PKCd.
The role of PKCd in apoptosis is complicated, and there are numerous reports of it acting both as a proapoptotic and an antiapoptotic factor, presumably depending on the apoptotic stimuli as well as the cell type (Li et al., 1999; Mandil et al., 2001; Brodie and Blumberg, 2003; Clark et al., 2003; Ni et al., 2003) . Importantly, PKCd was recently reported to be a prosurvival factor in human breast cancer cell lines (McCracken et al., 2003) . The authors of that study showed that Rottlerin, as well as expression of a dominant-negative PKCd or a PKCd antisense, reduced cell survival in both MDA-MB-231 and MCF-7 cells. The PKCd antisense also sensitized the cells to the apoptotic effects of gamma-radiation. Thus, it is possible that the apoptosis observed in MDA-MB-231 cells upon treatment with RA þ GF, RA þ Go or RA þ Rottlerin is caused, at least partially, by reduced PKCd activity or levels. This conclusion was supported by siRNA studies, where a PKCd siRNA selectively conferred enhanced sensitivity to RA (see Figure 9) . However, Rottlerin has also been reported to cause cell death independently of PKCd (Tillman et al., 2003) , and it cannot be ruled out that GF and Go may also stimulate apoptotic pathways independently of their effects on PKC. Again, our siRNA studies supported this possibility. Although close to complete knockout of PKCd was achieved, and this caused an increase in RA response, addition of GF still significantly enhanced the effect. This strongly suggests that GF (as well as Go and Rottlerin) has an effect in addition to inhibition of PKC, which is required for full stimulation of retinoid-induced apoptosis. Our evidence further suggests that this effect entails activation of ERK, since GF, Go and Rottlerin In fact, we found that levels of both phospho-ERK and phospho-p38 MAPK are significantly increased by GF. Activation of ERK occurs after as little as 3 h of treatment and is sustained for at least 72 h, whereas p38 is significantly activated only after 24 h. Moreover, inhibition of ERK, but not p38, almost completely suppresses induction of apoptosis by RA þ GF. This was unexpected, since ERK activation is usually associated with cell proliferation and not cell death (Johnson and Lapadat, 2002; Santen et al., 2002) . However, there are some reports in the literature of ERK acting as a proapoptotic molecule. For example, DNA-damaging agents such as etoposide, doxorubicin, cisplatin and UV radiation cause activation of ERK. This activation leads to either induction of the cyclin-dependent kinase inhibitor p21 and cell growth arrest, or apoptosis, and both can be inhibited by the MEK inhibitors PD98059 and U0126 (Persons et al., 2000; Wang et al., 2000; Tang et al., 2002; Lee et al., 2003) . Likewise, Resveratrol, a phytoalexin found in red wine, has been reported to induce apoptosis in various cancer cell types in an ERK-dependent manner (She et al., 2001; Lin et al., 2002; Shih et al., 2002) .
Crosstalk between the ERK pathway and retinoid signaling has been described previously, although the details of this crosstalk are far from clear and appear to be cell type dependent. There are several reports showing that ERK can inhibit retinoid signaling through phosphorylation of RXRa, which interferes with its transactivation function (Solomon et al., 1999; Matsushima-Nishiwaki et al., 2001; Adachi et al., 2002) . Retinoids also inhibit ERK activity in several cell lines, and this has been associated with growth inhibition (Sah et al., 2002; Crowe et al., 2003) . On the other hand, activation of ERK by RA is required for its ability to induce differentiation of HL-60 cells (Yen et al., 1998; Miranda et al., 2002) as well as differentiation of embryonic stem cells into adipocytes (Bost et al., 2002) .
To our knowledge, this report is the first example of ERK stimulating induction of apoptosis by RA. Although RA is known to cause growth arrest and differentiation in many tumor cell lines (Jiang et al., 1994; Giannini et al., 1997; Rosenauer et al., 1998; Hsu et al., 2000) , there are numerous cell types, including breast cancer cells, where RA and other retinoids also induce apoptosis (Nagy et al., 1995; Liu et al., 1996; Spanjaard et al., 1997; Mangiarotti et al., 1998; Lee et al., 2000b; Pettersson et al., 2002) . While activation of ERK has been implicated in apoptosis induced by other stimuli (Persons et al., 2000; Wang et al., 2000; Tang et al., 2002; Lee et al., 2003) , as well as induction of differentiation by RA (Yen et al., 1998; Miranda et al., 2002) , we show that RA in combination with several PKC inhibitors induces apoptosis in RA-resistant cells, through a mechanism that involves activation of ERK. The lack of response to UCN-01 þ RA can be explained by the fact that UCN-01 neither inhibits PKCd nor activates ERK in these cells.
It is unclear how inhibitors of PKC can activate MAPK signaling, but the fact that ERK is activated early, before any effects on PKC were observed (Figure 6 ), may suggest that a PKC-independent mechanism is responsible. Our studies using siRNA also showed that simply downregulating PKCa or d did not affect ERK activity (data not shown). Thus, further studies will be necessary in order to elucidate the mechanism. It is also not clear how RA and GF regulate PKC levels. At the RNA level, we observed only a weak downregulation of PKCa and no effect on PKCd. This indicates that the main regulation occurs at the protein level, suggesting that either the rate of protein synthesis is reduced or protein degradation is stimulated. PKCa and d are both subject to degradation via the proteasome, and PKCd is also a target of caspases and is cleaved during apoptosis (Lee et al., 1996; Denning et al., 1998; Lu et al., 1998) . Therefore, it is possible that the observed decrease in PKCa and d, as well as phospho-PKC, is a result of the fact that the cells are undergoing apoptosis after treatment with RA þ GF. In support of this, the decrease is only seen after 48-72 h, a time when the cells are starting to die. Interestingly, the MEK inhibitors PD98059 and U0126 were able to rescue the decrease in both total and phosphorylated PKC (Figure 7 and data not shown). This may of course imply that activation of MEK/ERK is necessary for degradation of PKC, but is perhaps more likely to reflect the fact that PD98059 and U0126 block apoptosis. Thus, in summary, the ability of the PKC inhibitors to stimulate retinoid-induced apoptosis may require inhibition/downregulation of PKC, and appear to involve PKCd in particular. In addition, a sustained activation of ERK1/2 is required, but further studies will be needed to elucidate the link between these events.
Although retinoids have shown promising preclinical antitumor activity in numerous models, successful clinical use has been mainly limited to APL, a disease characterized by expression of fusion oncoproteins invariably involving RARa (Mann et al., 2001) . Numerous synthetic retinoids with a more favorable activity than RA have been developed, some of which are in clinical trials from which the outcome is yet to be reported. In order to increase the activity of retinoids against breast cancer, and particularly ER-negative disease, we examined the possibility of combination therapy using kinase inhibitors. Our results showing a strong growth inhibitory response to RA in combination with several PKC inhibitors are encouraging, especially since two synthetic retinoids, TTNPB and Bexarotene, also cause apoptosis in MDA-MB-231 when combined with GF. In view of recent advances that have been made in the development of cancer therapies that specifically target various signal transduction pathways, further research is warranted to investigate whether the combination of retinoids with such drugs may enhance the activity of retinoids in the clinical treatment of breast cancer.
Materials and methods
Drugs and reagents
The PKC inhibitors GF109203X, Go6983 and Rottlerin, the p38MAPK inhibitor SB203580 and the MEK inhibitor U0126 were purchased from Calbiochem. The MEK inhibitor PD98059 was purchased from Sigma. The JNK inhibitor SP600125 was purchased from Biomol. UCN-01 was obtained from Dr RJ Schultz at the Drug synthesis and Chemistry Branch, NCI, Bethesda, MD, USA. The compounds were dissolved in DMSO and kept at À201C. All-trans-retinoic acid was purchased from Sigma and TTNPB (LG100272) and Bexarotene (Targretin s , LGD1069) were obtained from Ligand Pharmaceuticals Inc., San Diego, CA, USA. The retinoids were dissolved in DMSO at a concentration of 10 mM and stored in the dark at À701C.
Cell culture
MDA-MB-231 cells (ATCC) were routinely maintained in alpha-MEM (Invitrogen) supplemented with 5% fetal bovine serum (FBS) at 371C in a humidified atmosphere containing 5% CO 2 . During all treatment experiments, cells were cultured in phenol red-free alpha-MEM with 2 or 5% charcoal-stripped serum (CSS).
Cell proliferation studies
Cells were seeded in 24-well plates at a density of 2000 cells/ well. The next day, fresh media containing DMSO or the inhibitory compounds was added. On the days indicated, cells were fixed in 10% trichloroacetic acid and subsequently stained with sulforhodamine B (SRB, Sigma). SRB is an aminoxanthene dye, which binds to basic amino-acid residues and gives an index of culture cell protein that is linear with cell number (Skehan et al., 1990) . Bound SRB was solubilized in 10 mM unbuffered Tris and optical density was measured at 570 nm in a microplate reader.
Cell cycle analysis and apoptosis assays
For these experiments, cells were treated with 10 mM RA and 1 mM GF109203X for 72 h, unless otherwise indicated. Propidium iodide (PI) staining followed by flow cytometry was used to analyse distribution of the cells in the different phases of the cell cycle, as well as to detect cells with a sub-G1 DNA content. Cells were seeded in six-well plates at a density of 5 Â 10 4 cells/well and the next day fresh media containing DMSO or the inhibitory compounds was added. On day 3, cells were trypsinized, washed twice with sample buffer (PBS þ 1g/l glucose) and fixed in 70% ethanol at a density of 5 Â 10 5 -1 Â 10 6 cells/ml. After a minimum of 18 h, cells were washed with sample buffer, resuspended in PI staining solution containing 50 mg/ml PI and incubated at room temperature for 30 min. Fluorescence was measured on a Becton-Dickinson FACSCalibur. Cell cycle analysis was performed using ModFit LT software and cells with sub-G1 DNA content were quantified using CellQUEST software.
Activation of caspase-3 was detected using a fluorescent caspase-3 inhibitor, Red-DEVD-FMK (Oncogene), which irreversibly binds to activated caspase-3 in apoptotic cells. Treated cells were trypsinized, resuspended in 300 ml culture media and incubated in the presence of 1 ml Red-DEVD-FMK for 1 h at 371C. Cells were then washed, resuspended and analysed by flow cytometry, using the FL-2 channel.
Apoptosis was also assessed using Annexin V-FITC staining (BD Biosciences), according to the protocol recommended by the manufacturer. Briefly, cells treated as indicated were trypsinized, washed twice with PBS, resuspended in 1 Â binding buffer and stained with Annexin V-FITC and PI for 15 min in the dark. Fluorescence was measured on a BectonDickinson FACSCalibur and FITC vs PI dotblots were analysed using CellQuest software.
Transient transfections
Cells were seeded into six-well plates at a density of 5 Â 10 4 cells/well. The next day, fresh media containing 5% CSS was added and cells were pretreated with GF (1 mM) or vehicle (DMSO). After 48 h, fresh media containing no treatment was added and the cells were cotransfected with bRARE-tk-CAT or CRBPII-tk-CAT (1 mg/well) plus pCMV-bgal (1 mg/well), using FuGENE transfection reagent (Roche Biochemicals) as specified by the manufacturer. At 4-5 h post-transfection, RA (1 mM), GF (1 mM), RA þ GF Bex (1 mM), Bex þ GF or vehicle was added and the cells were harvested 48 h post-transfection. b-Gal activity and CAT activity were assayed as previously described (Rosenauer et al., 1998) .
Western blotting
Whole cell lysates were prepared by washing the cells in icecold PBS, resuspending them in lysis buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1% Triton X-100 plus protease and phosphatase inhibitors) followed by incubation on ice and microcentrifugation at maximum speed for 10 min to exclude insoluble material. Protein concentrations were determined by the Bradford assay (BioRad). Equal amounts of protein (15-80 mg) were electrophoretically separated in 10% SDS-polyacrylamide gels and proteins were immobilized by transfer onto nitrocellulose membranes. Membranes were immunoprobed with antibodies to PKCa (Transduction laboratories), PKCd (Santa Cruz), phospho-PKC, phospho-ERK and phospho-p38MAPK (Cell Signaling Technologies), ERK2 (SantaCruz), PARP (Oncogene) and b-actin (Sigma) followed by a secondary, peroxidase-labeled antibody. The proteins were visualized by enhanced chemiluminescence (ECL, Amersham Biosciences).
Kinase assay
Whole cell extracts were prepared as described above. For assessment of JNK activity, 200 mg of protein extracts were subjected to immunoprecipitation with an antibody specific to JNK1 (Santa Cruz). The cell extracts were incubated with 1 mg of the antibody and 20 ml packed Protein A sepharose CL-4B beads (Amersham) in a total volume of 200 ml for 1 h at 41C. The immunoprecipitates were washed with 1 Â kinase buffer (25 mM HEPES pH 7.5, 25 mM b-glycerophosphate, 25 mM MgCl 2 , 1mM NaOV 4 , 1mM DTT) and subsequently incubated with 1 mg GST-c-Jun in 2 Â kinase buffer containing 2 mCi [ 32 P]g-ATP. The reaction was terminated by addition of binding buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.1% NP-40) followed by centrifugation at maximum speed for 1 min. The supernatant was transferred to a new tube and GST-c-Jun was pulled down by incubation with Glutathione sepharose-4B beads (Amersham) for 1 h at 41C. The beads were washed three times with binding buffer, resuspended in SDS-PAGE loading buffer and boiled for 5 min. Supernatants were separated by SDS-PAGE and phosphorylated c-Jun was visualized by autoradiography.
RNA interference
21-nucleotide siRNAs (HPP grade) were chemically synthesized by Xeragon oligonucleotides (Xeragon-Qiagen). The sequences of each siRNA pairs were as follows: PKCa 5 0 -AAA GGC UGA GGU UGC UGA UTT-3 0 and 5 0 -AUC AGC AAC CUC AGC CUU UTT-3 0 ; PKCd 5 0 -CGA CAA GAU CAU CGG CAG ATT-3 0 and 5 0 -UCU GCC GAU GAU CUU GUC GTT-3 0 (Irie et al., 2002) . 20 mM siRNA duplexes were generated by annealing of sense and antisense nucleotides as specified by the supplier and transfection was performed using TransMessengert transfection reagent (Qiagen). Cells were seeded in six-well plates at a density of 1 Â 10 5 cells/well. The next day, cells were transfected with siRNA (4 mg/well) as recommended by the manufacturer, using a ratio of RNA : -TransMessengert of 1 : 3. After a 2.5 h incubation period, transfection complexes were removed, the cells washed twice with PBS, and regular growth media added. For apoptosis assessment, drugs were added after another 3-4 h and cells were harvested for PI staining and flow cytometry analysis 72 h post-transfection.
Statistics
All experiments were performed at least three times and results from representative experiments are shown as means of the number of replicates indicated in each figure. To evaluate statistical significance for growth, apoptosis and transcription experiments, one-way ANOVA with Dunnett's post-test was performed using GraphPad Prism version 3.0. Significant differences compared to control (untreated cells) are shown, unless otherwise stated. *Po0.05, **Po0.01.
